Discordance Between HbA1c and Fructosamine
- 1 January 2003
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (1) , 163-167
- https://doi.org/10.2337/diacare.26.1.163
Abstract
OBJECTIVE—Discordances between HbA1c and other measures of glycemic control are common in clinical practice and remain unexplained. We developed a measure of discordance between HbA1c and fructosamine (FA) (glycosylated serum proteins) to conduct a systematic evaluation. We termed this the glycosylation gap (GG) and sought to determine its relationship to diabetic nephropathy. RESEARCH DESIGN AND METHODS—Measurements of HbA1c and FA on the same sample in 153 people were used to calculate GG, defined as the difference between measured HbA1c and HbA1c predicted from FA based on the population regression of HbA1c on FA. RESULTS—GG had a broad distribution (range, −3.2% to 5.5%); 40% of samples had values indicating major differences in prediction of complications risk by the measured versus predicted HbA1c. GG was highly correlated (r = 0.81) between measurements repeated in 65 patients 23 ± 2 weeks apart, indicating that the discordances are reliable and not explained by differences in turnover of underlying proteins. In 40 patients with type 1 diabetes of ≥15 years’ duration, an increase in GG by 1% was associated with a 2.9-fold greater frequency of increasing nephropathy stage (P = 0.0014). GG was −0.8 ± 0.2% in subjects with no nephropathy, −0.3 ± 0.2% with microalbuminuria/hypertension, and 0.7 ± 0.3% in subjects with proteinuria or renal dysfunction (P < 0.05). GG correlated better with nephropathy than did either HbA1c or FA alone in this population. CONCLUSIONS—The glycosylation gap may be a useful clinical research tool for evaluating physiologic sources of variation in diabetic complications beyond glycemic control.This publication has 34 references indexed in Scilit:
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis.Journal of Clinical Investigation, 1998
- Microalbuminuria in NIDDM is caused by increased excretion of unmodified albuminDiabetes, 1996
- Carbamylated Hemoglobin in Prerenal AzotemiaNephron, 1995
- Fructosamine and glycated haemoglobin in the assessment of long term glycaemic control in diabetes.Archives of Disease in Childhood, 1994
- An Analysis of Glycosylated Blood Proteins and Blood Glucose Profiles Over One Year in Patients with Type 1 DiabetesDiabetic Medicine, 1989
- The Clinical Information Value of the Glycosylated Hemoglobin AssayNew England Journal of Medicine, 1984
- Proteinuria and functional characteristics of the glomerular barrier in diabetic nephropathyKidney International, 1980
- HÆMOGLOBIN A1: AN INDICATOR OF THE METABOLIC CONTROL OF DIABETIC PATIENTSThe Lancet, 1977
- Clinical Physiology: Increased Metabolic Turnover Rate and Transcapillary Escape Rate of Albumin in Long-Term Juvenile DiabeticsScandinavian Journal of Clinical and Laboratory Investigation, 1975